Protein-Protein Interactions as Underlying Regulatory Mechanisms of Drug-metabolizing Enzyme Function

被引:0
|
作者
Miyauchi, Yuu [1 ]
机构
[1] Sojo Univ, Fac Pharmaceut Sci, Nishi Ku, 4-22-1 Ikeda, Kumamoto 8600082, Japan
关键词
CYP; uridine 5 '-diphospho-glucuronosyltransferase; protein-protein interaction; drug metabolism; inter-individual difference; endoplasmic reticulum membrane; UDP-GLUCURONOSYLTRANSFERASE; LIVER-MICROSOMES; CYTOCHROME-P450; MODULATION;
D O I
10.1248/yakushi.22-00124
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cytochrome P450 (P450, CYP) and uridine 5 '-diphospho-glucuronosyltransferase (UGT) are major drug-metabolizing enzymes known to catalyze substrate oxidation and glucuronidation, respectively. Both enzymes are located within the endoplasmic reticulum (ER) membrane; however, their membrane topologies diSer, with P450 facing cytosol and a major part of UGTs located on the luminal side. Because of the large differences in the reactions that they catalyze and their membrane topologies, it had been believed that P450 and UGT function separately. However, some chemicals are oxidized by P450 and undergo further conjugation by UGT. Therefore, it is important to consider that P450 and UGT may form a complex within the ER membrane and regulate each other's function through this interaction. To prove this hypothesis, we constructed a co-expression system for CYP3A4, P450 reductase, and UGT2B7/1A9 with a baculovirus-insect cell expression system. This system allowed us to compare CYP3A4 activity in the presence and absence of UGT2B7/1A9 co-expression and revealed that the UGTs suppress CYP3A4 activity. The suppressive eSect of UGT2B7 was not limited to the enzymatic activity of CYP3A4 but also extended to the entire catalytic cycle, which may be resulted from the inhibition of substrate-binding to the P450. Analysis using UGT mutants indicated that one of the hydrophobic regions within the luminal portion of the UGT interacts with CYP3A4. Furthermore, we suggested that UGT1A suppresses CYP3A activity in vivo by treating rats with dexamethasone. Thus, the functional interactions between P450 and UGT would advance our understanding of the large inter-individual differences in drug-metabolizing capacity.
引用
收藏
页码:1169 / 1175
页数:7
相关论文
共 50 条
  • [21] Databases of protein-protein interactions and their use in drug discovery
    Fuentes, Gloria
    Oyarzabal, Julen
    Rojas, Ana M.
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2009, 12 (03) : 358 - 366
  • [22] Editorial: Protein-Protein Interactions: Drug Discovery for the Future
    Rapposelli, Simona
    Gaudio, Eugenio
    Bertozzi, Fabio
    Gul, Sheraz
    FRONTIERS IN CHEMISTRY, 2021, 9
  • [23] Triazabutadiene drug conjugates for the identification of protein-protein interactions
    Shepard, Abigail
    Jewett, John
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 255
  • [24] Computational Drug Design Targeting Protein-Protein Interactions
    Bienstock, Rachelle J.
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (09) : 1240 - 1254
  • [25] Structural Instability Tuning as a Regulatory Mechanism in Protein-Protein Interactions
    Chen, Li
    Balabanidou, Vassilia
    Remeta, David P.
    Minetti, Conceicao A. S. A.
    Portaliou, Athina G.
    Economou, Anastassios
    Kalodimos, Charalampos G.
    MOLECULAR CELL, 2011, 44 (05) : 734 - 744
  • [26] Structural biology and drug discovery for protein-protein interactions
    Jubb, Harry
    Higueruelo, Alicia P.
    Winter, Anja
    Blundell, Tom L.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2012, 33 (05) : 241 - 248
  • [27] Motif mediated protein-protein interactions as drug targets
    Corbi-Verge, Carles
    Kim, Philip M.
    CELL COMMUNICATION AND SIGNALING, 2016, 14
  • [28] Beyond Competitive Inhibition: Regulation of ABC Transporters by Kinases and Protein-Protein Interactions as Potential Mechanisms of Drug-Drug Interactions
    Crawford, Rebecca R.
    Potukuchi, Praveen K.
    Schuetz, Erin G.
    Schuetz, John D.
    DRUG METABOLISM AND DISPOSITION, 2018, 46 (05) : 567 - 580
  • [29] The ontogeny of human drug-metabolizing enzymes: Phase II conjugation enzymes and regulatory mechanisms
    McCarver, DG
    Hines, RN
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 300 (02): : 361 - 366
  • [30] NMR studies of enzyme-substrate and protein-protein interactions
    Roberts, GCK
    DYNAMICS AND THE PROBLEM OF RECOGNITION IN BIOLOGICAL MACROMOLECULES, 1996, 288 : 37 - 47